Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells

Immunobiology

Volumn 197, Issue 5, 1997, Pages 444-459

  Juhl, Hartmut ^a,c   Petrella, Eugene C ^a,d   Cheung, Nai Kong V ^b   Bredehorst, Reinhard ^a,e   Vogel, Carl Wilhelm ^a,e  

^a GEORGETOWN UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COBROTOXIN; COMPLEMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; COMPLEMENT SYSTEM; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 0030716387     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0171-2985(97)80078-2     Document Type: Article

References (46)

1. WALDMANN, T. A. 1991. Monoclonal antibodies in diagnosis and therapy. Science 252: 1657.
2. GROSSBARD, M. L., and L. M. NADLER. 1992. Immunotoxin therapy of malignancy. In Important Advances in Oncology (Edited by De Vita, V. T., S. HELLMANN, and S. A. ROSENBERG), J. Lippincott Co., Philadelphia, 111 pp.
3. LOBUGLIO, A. F., and M. N. SALEH. 1992. Advances in monoclonal antibody therapy of cancer. Am. J. Med. Sci. 304: 214.
4. PIETERSZ, G. A., and I. F. C. MCKENZIE. 1992. Antibody conjugates for the treatment of cancer. Immunol. Rev. 129: 57.
5. MILLER, R. A., D. C. MALONEY, R. WARNKE, and R. LEVY. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306: 517.
6. SEARS, H. F., D. HERLYN, Z. STEPLEWSKY, and H. KOPROWSKI. 1985. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 45: 5910.
7. D3 ganglioside: A Phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 82: 1242.
8. D2. Proc. Natl. Acad. Sci. USA 83: 8694.
9. D2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 5: 1430.
10. SCHULTZ, G., L. K. STAFFILENO, R. A. REISFELD, and G. DENNERT. 1985. Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells. J. Exp. Med. 161: 1315.
11. CHEUNG, N.-K. V., U. M. SAARINEN, J. E. NEELY, B. LANDMEIER, D. DONOVAN, and P. F. COCCIA. 1985. Monoclonal antibody to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 45: 2642.
12. MUNN, D. H., C. CORDON-CARDO, S. D. J. YEH, B. H. KUSHNER, and N.-K. V. CHEUNG. 1989. Therapy of neuroblastoma with GD2 specific antibody 3F8. In Gangliosides and Cancer (Edited by OETTGEN, H. F.). VCH Verlagsgesellschaft, Weinheim, Basel, Cambridge, New York, pp. 259.
13. VOGEL, C.-W. 1987. Antibody conjugates without inherent toxicity: the targeting of cobra venom factor and other biological response modifiers. In Immunoconjugates. Antibody Conjugates in Radioimaging and Therapy of Cancer (Edited by VOGEL, C.-W). Oxford University Press, Oxford, New York, pp. 170.
14. VOGEL, C.-W. 1990. Cobra venom factor, the complement-activating protein of cobra venom. In Handbook of Natural Toxins, vol. 5: Reptile and Amphibian Venoms (Edited by TU, A. T.), Marcel Dekker, New York, pp. 147.
15. LACHMANN, P. J., and L. HALBWACHS. 1975. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin. Exp. Immunol. 21: 109.
16. ALPER, C. A., and D. BALAVITCH. 1976. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 191: 1275.
17. NAGAKI, K., K. IIDA, M. OKUBO, and S. INAI. 1978. Reaction mechanism of beta-1H globulin. Int. Arch. Allergy Appl. Immunol. 57: 221.
18. VOGEL, C.-W., and H. J. MÜLLER-EBERHARD. 1981. Induction of immune cytolysis: tumor cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase. Proc. Natl. Acad. Sci. USA 78: 7707.
19. VOGEL, C.-W., S. D. WILKIE, and A. C. MORGAN. 1985. In vivo studies with covalent conjugates of cobra venom factor and monoclonal antibodies to human tumors. In Modern Trends in Human Leukemia VI (Edited by NETH, R., R. C. GALLO, M. F. GRAEVES and G. JANKA), Springer Verlag Berlin, Heidelberg, pp. 514.
20. MÜLLER, B., H. HARPRECHT, M. J. D. ANDERSON, and W. MÜLLER-RUCHHOLTZ. 1986. Activation of human complement by covalent conjugates of mouse monoclonal antibodies and cobra venom factor. Br. J. Cancer 54: 537.
21. MÜLLER, B., and W. MÜLLER-RUCHHOLTZ. 1986. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation. Leukemia Res. 11: 461.
22. MÜLLER, B., and W. MÜLLER-RUCHHOLTZ. 1986. In vitro killing of target cells by antibody/ ricin or antibody/cobra venom factor conjugates: comparison of selectivity and potency. Immunobiology 173: 195.
23. 2cobra venom factor conjugate are equally cytotoxic. Mol. Immunol. 27: 957.
24. VOGEL, C.-W., and H. J. MÜLLER-EBERHARD. 1984. Cobra venom factor: improved method for purification and biochemical characterization. J. Immunol. Meth. 73: 203.
25. D2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 47: 5377.
26. PETRELLA, E. C., S. D. WILKIE, C. A. SMITH, A. C. MORGAN, Jr., and C.-W. VOGEL. 1987. Antibody conjugates with cobra venom factor: synthesis and biochemical characterization. J. Immunol. Meth. 104: 159.
27. VOGEL, C.-W. 1988. Synthesis of antibody conjugates with cobra venom factor using heterobifunctional crosslinking reagents. In Antibody Delivery Systems (Edited by RODWELL, J. D.), Marcel Dekker, New York, pp. 191.
28. PANNEERSELVAM, M., S. WELT, L. J. OLD, and C.-W. VOGEL. 1986. A molecular mechanism of complement resistance of human melanoma cells. J. Immunol. 136: 2534.
29. LOWRY O. H., N. J. ROSEBROUGH, A. L. FARR, and R. J. RANDALL. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265.
30. D2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem. Biophys. Res. Comm. 127: 1.
31. FRITZINGER, D. C., R. BREDEHORST, and C.-W. VOGEL. 1994. Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. USA 91: 12775.
32. KOCK, M. A., P. ZIEGELMÜLLER, R. BREDEHORST, and C.-W. VOGEL. 1996. Recombinant expression of active cobra venom factor (CVF). Mol. Immunol. 33 (Suppl. 1): 15.
33. VOGEL, C.-W., and R. BREDEHORST. 1997. Immunoconjugates. In Encyclopedia of Human Biology, 2nd Edition (Edited by DULBECCO, R.), Academic Press, San Diego, in press.
34. STONG, R. C., F. UCKUN, R. J. YOULE, J. H. KERSEY, and D. A. VALERA. 1985. Use of multiple T cell-directed ricin immunotoxins for autologous bone marrow transplantation. Blood 66: 627.
35. KATZ, F. E., G. JANOSSY, A. CUMBER, W. ROSS, H. A. BLACKLOCK, W. TAX, and P. E. THORPE. 1987. Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Brit. J. Haematol. 67: 407.
36. GHETIE, M.-A., K. TUCKER, J. RICHARDSON, J. W. UHR, and E. S. VITETTA. 1992. The anti-tumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 80: 2315.
37. ENGERT, A., C. GOTTSTEIN, H. BOHLEN, U. WINKLER, G. SCHÖN, O. MANSKE, R. SCHNELL, V. DIEHL, and P. THORPE. 1995. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int. J. Cancer 63: 304.
38. MAILLARD, J. L., and R. M. ZARCO. 1968. Decomplementation par un facteur du venom de cobra. Effet sur plusieures reactions immunes de cobaye et du rat. Ann. Inst. Pasteur 114: 756.
39. PERLMANN, H., P. PERLMANN, R. D. SCHREIBER, and H. J. MÜLLER-EBERHARD. 1981. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. J. Exp. Med. 153: 1592.
40. MORGAN, E. L., W. O. WEIGLE, and T. E. HUGLI. 1984. Anaphylatoxin-mediated regulation of human and murine immune responses. FASEB J. 43: 2543.
41. 99 mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Cancer Res. (Suppl.) 55: 5749s.
42. GOWDA, D. C., M. SCHULTZ, R. BREDEHORST, and C.-W. VOGEL. 1992. Structure of the major oligosaccharide of cobra venom factor. Mol. Immunol. 29: 335.
43. GOWDA, D. C., E. C. PETRELLA, T. T. RAJ, R. BREDEHORST, and C. W. VOGEL. 1994. Immunoreactivity and function of oligosaccharides in cobra venom factor. J. Immunol. 152: 2977.
44. GALILI, U., M. R. CLARK, S. B. SHOHET, J. BUEHLER, and B. A. MACHER. 1987. Evolutionary relationships between the natural anti-Gal antibody and the Galα1→3Gal epitope in primates. Proc. Natl. Acad. Sci. USA 84: 1369.
45. O'KEEFE, M. C., L. H. CAPORALE, and C.-W. VOGEL. 1988. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J. Biol. Chem. 263: 12690.
46. FRITZINGER, D. C., E. C. PETRELLA, M. B. CONNELLY, R. BREDEHORST, and C.-W. VOGEL. 1992. Primary structure of cobra complement component C3. J. Immunol. 149: 3554.